|
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
Stock Quote
NASDAQ: CCXI
Price:
12.55
Change:
+ 0.08
Day High:
12.75
Day Low:
12.49
Volume:
14,000
4:00 PM ET on May 17, 2012
Delayed at least 20 minutes. Provided by eSignal.
May 10, 2012
ChemoCentryx Announces First Quarter 2012 Financial Results
Apr 30, 2012
ChemoCentryx Appoints Joseph M. Feczko, M.D. to Company's Board of Directors
Apr 12, 2012
ChemoCentryx to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
^ Return to Top
|